De-novo mutations in patients with chronic ultra-refractory epilepsy with onset after age five years by ,
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De-novo mutations in patients with chronic ultra-refractory
epilepsy with onset after age five years
Citation for published version:
EPIGEN Consortium 2019, 'De-novo mutations in patients with chronic ultra-refractory epilepsy with onset
after age five years', European journal of medical genetics. https://doi.org/10.1016/j.ejmg.2019.01.015
Digital Object Identifier (DOI):
10.1016/j.ejmg.2019.01.015
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available
Published In:
European journal of medical genetics
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Contents lists available at ScienceDirect
European Journal of Medical Genetics
journal homepage: www.elsevier.com/locate/ejmg
De-novo mutations in patients with chronic ultra-refractory epilepsy with
onset after age five years
Mark McCormacka,b, Ronan N. McGintyc,d, Xiaolin Zhue, Lisa Slatteryf, Erin L. Heinzene, the
EPIGEN Consortium, Daniel J. Costelloc, Norman Delantya,g,h, Gianpiero L. Cavalleria,h,∗
a Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Ireland
bDepartment of Genetics, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
c Department of Neurology, Cork University Hospital, Wilton, Cork, Ireland
dNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom
e Institute for Genomic Medicine, Columbia University Medical Center, New York, NY, USA
fDepartment of Neurology, St. James' Hospital, Dublin 8, Ireland
g Department of Neurology, Beaumont Hospital, Dublin 9, Ireland
h The FutureNeuro Research Centre, RCSI, Dublin, Ireland
A R T I C L E I N F O
Keywords:
Epilepsy
Pharmacoresistance
Genetic
Exome sequencing
A B S T R A C T
We set out to investigate whether a de-novo paradigm could explain genetic causes of chronic ultra-refractory
epilepsy, with onset later than the typical age for the epileptic encephalopathies. We performed exome se-
quencing on nine adult patients with MRI-negative epilepsy and no preceding intellectual disability. All had an
onset of seizures after five years old and had chronic ultra-refractory epilepsy defined here as having failed more
than six anti-epileptic drugs and currently experiencing ≥4 disabling seizures per month. Parents were se-
quenced to identify de-novo mutations and these were assessed for likelihood of pathogenicity based on the
American College of Medical Genetics and Genomics (ACMG) criteria. We confirmed the presence of functional
and predicted-damaging de-novo mutations in 3/9 patients. One of these pathogenic de-novo mutations, in
DNM1L, was previously reported in a patient with severe epilepsy and chronic pharmacoresistance adding to the
evidence for DNM1L as an epilepsy gene. Exome sequencing is a successful strategy for identifying de-novo
mutations in paediatric epileptic encephalopathies and rare neurological disorders. Our study demonstrates the
potential benefit of considering ultra-refractory epilepsy patients with later onset for genetic testing. Identifying
genetic mutations underpinning severe epilepsy of unknown aetiology may provide new insight into the un-
derlying biology and offers the potential for therapeutic intervention in the form of precision medicine in older
patients.
1. Introduction
Many patients with chronic refractory epilepsy develop seizures
early in life (before age five), often as a manifestation of an underlying
epileptic encephalopathy, along the West syndrome or Lennox-Gastaut
syndrome phenotypic spectrum. A significant percentage of young
children diagnosed with such an epileptic encephalopathy have a mu-
tation in one of an increasing number of key genes involved in early
brain development or in critical neuroregulatory functions such as sy-
naptogenesis and cell cycle control (He et al., 2018). However, a sig-
nificant number of patients develop refractory epilepsy and often sec-
ondary cognitive regression with onset after age five and after normal
early neurodevelopment. Many of these patients can be described as
having “ultra-refractory” epilepsy with a high seizure density and
failure of many different AEDs to have a positive impact on seizure
control.
An important paradigm in the genetic underpinnings of epilepsy is
the pathological impact of de-novo mutations (Goldstein et al., 2013).
Indeed, the importance of such mutations to epileptic encephalopathies
has been appreciated for some time, but the application of next-gen-
eration sequencing is increasingly illustrating the nature and extent of
the contribution (Allen et al., 2013). While some patients with epilepsy
onset after age five will have an underlying structural brain epilepto-
genic lesion e.g. focal cortical dysplasia, many are non-lesional or ‘MRI-
negative’. The role of de-novo mutations in chronic refractory, later
onset epilepsy is poorly understood. Understanding the genetic factors
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underlying epilepsy predisposition and treatment is vital for identifying
much-needed diagnostic markers to help individualize patient care. We
set out to determine the diagnostic yield of exome sequencing in a series
of sporadic ultra-refractory epilepsy trios with onset greater than five
years of age.
1.1. Patient data
We recruited subjects through epilepsy clinics associated with the
EPIGEN Consortium at Beaumont and St. James’ Hospitals, (Dublin)
and Cork University Hospital (Cork) in Ireland (Sen et al., 2018). All
study participants provided written, informed consent for genetic
analysis. Local institutional review boards approved study protocols at
each site. Our inclusion criteria were as follows: adult patients
(> 18 years at recruitment) with active epilepsy,≥ four seizures of any
kind per month at recruitment (estimated from prior 12 months),
failed≥ six appropriate anti-epileptic drugs and an age of seizure
onset > five years old. Subjects with an explanatory lesion on MRI, a
preceding learning disability or first degree relative with epilepsy were
excluded. Phenotype details were collected through clinical interactions
and from hospital patient records.
2. Methods
We sequenced the exomes of nine probands and their unaffected
parents. Five trios (UR001, UR007, UR008, UR011 and UR012) were
sequenced at Columbia University Institute for Genomic Medicine (NY,
USA) using the Roche NimbleGen SeqCap EZ Exome target enrichment
platform on an Illumina HiSeq. A further four trios (UR002, UR003,
UR004, UR005) were sequenced at Edinburgh Genomics (Scotland, UK)
using the Ion Xpress Plus Fragment Library Kit enrichment platform on
an Ion Personal Genome Machine. Paired-end or single read FASTQ files
were aligned to human reference genome build GRCh37 with samtools
and Burrows Wheeler Aligner (BWA) (Li and Durbin, 2009). Duplicate
reads were checked and removed with Picard tools. Variant calling was
performed with Genome Analysis Toolkit Haplotype Caller (GATK v3.0)
according to the best practices pipeline (Depristo et al., 2011). Variants
were phased with parental sequences to identify de-novo mutations
assuming a prior de-novo rate of 1×10−6. Variants were filtered for
genotype quality (GQ > 20) and read depth (> 10x) and the final set
of variants were annotated with ANNOVAR (Wang et al., 2010). We
used the tools Sorting Intolerant from Tolerant (SIFT), Polyphen-2 and
Combined Annotation Dependent Depletion (CADD) for in silico pre-
dictions of the functional effect of missense mutations.
We defined ‘qualifying variants’ as those that satisfied each of the
following criteria: i) de-novo ii) minor allele frequency= 0 in gnomAD
(http://gnomad.broadinstitute.org/), iii) missense or loss of function or
frameshift or affecting a splice-site and iv) if missense, in silico predicted
damaging by SIFT, Polyphen-2 or a CADD phred-scaled score > 10. In
the event of a recessive disease, we also investigated homozygous
variants with the same filtering criteria, but a minor allele fre-
quency<0.001 in gnomAD. We did not consider segregating reduced
penetrance heterozygous variants since all cases had unaffected parents
and no family history of seizure disorder. Qualifying variants were
confirmed by Sanger sequencing. We followed ACMG guidelines to
determine the pathogenicity of qualifying variants (Richards et al.,
2015).
3. Results
A description of our case series is provided in Table 1.
We sequenced>84% of the protein coding region at least 10 fold.
Qualifying variants identified by exome sequencing are listed in
Table 2.
We detected functional and predicted-damaging de-novo mutations
in three probands. On analysis of the candidate variants using ACMG Ta
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classification criteria, we could determine that UR3 had a pathogenic
mutation in the gene DNM1L. There was insufficient evidence to assign
pathogenicity to the variants detected in UR1. We did not observe any
qualifying de-novo or recessive mutations in the probands UR2, UR4,
UR5, UR7, UR8, UR10, UR11 or UR12.
4. Discussion
We present an exome sequencing case series of a severe, late-onset,
sporadic refractory epilepsy. In all, we identified qualifying de-novo
mutations in over half of our cases.
A single qualifying de-novo mutation in OPLAH was observed in
proband UR1. OPLAH is associated with autosomal recessive 5-ox-
oproline deficiency however there is a single report of a heterozygous
(S323R) paediatric patient with excessive urine pyroglutamic acid and
seizure-onset at six weeks (Calpena et al., 2013). A follow-up urine
organic acid metabolic screen of UR1 did not reveal excess pyr-
oglutamate or any dysfunction of organic acid metabolism, therefore
we concluded G28R to be a variant of unknown significance (VUS).
Three qualifying de-novo mutations were found in proband UR3.
Two of these, D360N in OSBPL7 and I304L in CEP55, were concluded to
be variants of unknown significance. The third de-novo found in this
proband is an R403C missense mutation in DNM1L. R40C is predicted
to be highly deleterious, is absent from control populations, resides at a
highly conserved amino acid and has been previously reported in the
literature and in public databases (ClinVar variant ID: 214313).
Therefore, it satisfies the criteria for pathogenicity according to ACMG
guidelines. Of the previous report, the first describes an infant with
refractory epilepsy and global developmental delay and experiencing
generalised tonic-clonic seizures with episodes of status epilepticus
beginning at one year old. This subject's EEG showed epileptiform ac-
tivity in frontal and central regions yet MRI was normal (Vanstone
et al., 2016). Meanwhile, two other carriers of this mutation had a
delayed seizure onset, with episodes of status epilepticus following
minor metabolic insult, preceding a rapidly progressing refractory en-
cephalopathy with myoclonus and atrophy on MRI (Fahrner et al.,
2016). We note the striking similarities in the phenotype and neuro-
logical decline between our proband and that of the cases in the
Fahrner report. DNM1L is a member of the dynamin GTPase super-
family, is a mediator of mitochondrial and peroxisomal division and is
highly expressed across brain tissues (Koch et al., 2003). Taken to-
gether, the evidence for pathogenicity of the R403C mutation in DNM1L
cannot be disputed and highlights the importance of reporting candi-
date mutations in public databases.
5. Conclusion
In summary, from cohort of nine cases, we have identified a pa-
thogenic mutation in one patient. This study is too small to draw con-
clusions regarding a diagnostic yield for this patient subgroup. Yet the
DNM1L finding has demonstrated the potential benefit of considering
severe refractory patients with onset later than the typical age for the
epileptic encephalopathies for genetic testing. Further, as variant
calling algorithms improve we hope to include copy number variant
analysis from exome sequence data going forward which may in turn
increase the number of positive findings. Later-onset encephalopathy is
likely to be a composite of genetic disorders that present within the
earlier age of onset of the epileptic encephalopathies, and other more
unique disorders that present later in childhood, and perhaps beyond.
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